Retraction to: Leukemia
The authors have decided to retract this article [1] because after publication they discovered that the SKM1-R, OCI-AML2 and MOLM13 cell lines used were cross-contaminated with murine hematopoietic cells. The results obtained using these cell lines are therefore unreliable. The data presented on primary patient samples remains valid.
All authors agree with this retraction.
References
Dubois A, Furstoss N, Calleja A, Zerhouni M, Cluzeau T, Savy C et al. LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. Leukemia. 2019;33:1501–13.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41375-018-0336-1.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Dubois, A., Furstoss, N., Calleja, A. et al. Retraction Note: LAMP2 expression dictates azacytidine response and prognosis in MDS/AML. Leukemia 34, 2544 (2020). https://doi.org/10.1038/s41375-020-0969-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-020-0969-8
